The Imviva platform combines proprietary gene editing with advanced T-cell engineering to address the key challenges of allogeneic CAR-T therapy, including immune rejection and graft-versus-host disease. Our approach is designed to deliver durable, safe, effective allogeneic cell treatments for cancer and immune diseases.
Our platform is designed to overcome immune rejection through two complementary strategies:
We have engineered an immune-evasion receptor designed to sustain CAR-T activity while preserving host immune function.
We have ablated a negative regulator of immune cell function that contributes to immune rejection to enable evasion of host T- and NK-cell rejection.
ANSWER™ directly inhibits immune responses against the CAR-T, allowing therapeutic cells to survive and function longer. This synthetic receptor blocks immune rejection and avoids the unintended effects typical of natural ligands. Through the expression of multiple ANSWER™ receptors, Imviva’s CAR-T can engage a broad range of immune cells, enhancing their persistence.
ANSWER™ potentiates CAR-T function for more effective target cell elimination. It overcomes self-inhibition via the co-stimulatory intracellular domain, preserving CAR-T functionality. Simultaneously, it provides an in-cis “cloaking” effect that supports sustained activity in the host.
ANSWER™ selectively protects CAR-T cells while sparing the patient’s broader immune system, allowing natural immune functions to continue unimpeded.
